论文部分内容阅读
目的建立一种稳定、准确、可靠的测定人血浆中伏立康唑浓度的方法,并将其应用于临床,为伏立康唑临床个体化应用提供参考。方法用蛋白沉淀法处理血浆样品,采用HPLC法,使用Agela Technologies C_(18)(250 mm×4.6 mm,5μm)色谱柱,在流动相为甲醇-乙腈-磷酸盐缓冲液(30∶25∶45)、柱温为30℃、流速为1 m L·min~(-1)、检测波长为256 nm条件下检测血浆中伏立康唑的浓度,进行方法学考察后将其应用于临床。结果伏立康唑血药浓度为0.2~8 mg·L~(-1)时与峰面积之间呈良好线性关系(r=0.999 2);0.25、2、8 mg·L~(-1)3种质控样品的日内和日间RSD<10%;平均提取回收率为93.6%。结论所建立的方法准确度高、特异性强,适用于临床伏立康唑的治疗药物浓度监测。
OBJECTIVE To establish a stable, accurate and reliable method for the determination of voriconazole in human plasma and to apply it in clinical practice to provide a reference for the clinical application of voriconazole. Methods The plasma samples were processed by protein precipitation method. The samples were separated on a Agela Technologies C_ (18) (250 mm × 4.6 mm, 5 μm) column using a mobile phase of methanol-acetonitrile-phosphate buffer (30:25:45 ), The column temperature was 30 ℃, the flow rate was 1 m L · min -1, and the concentration of voriconazole in the plasma was detected at a detection wavelength of 256 nm. The method was applied to the clinical study. Results There was a good linear relationship between the concentration of voriconazole at the concentration of 0.2-8 mg · L -1 and the peak area (r = 0.999 2), 0.25, 2, 8 mg · L -1 Control samples within the day and day RSD <10%; average extraction recovery was 93.6%. Conclusion The established method has high accuracy and specificity and is suitable for the monitoring of clinical voriconazole concentration.